Literature DB >> 28679736

Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.

Kinkini N Magina1, Gudrun Pregartner2, Armin Zebisch1, Albert Wölfler1, Peter Neumeister1, Hildegard T Greinix1, Andrea Berghold2, Heinz Sill1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28679736     DOI： 10.1182/blood-2017-04-777722

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  19 in total

1.  Exposure time versus cytotoxicity for anticancer agents.

Authors:  David M Evans; Jianwen Fang; Thomas Silvers; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Michael Selby; Lori Bowles; John Connelly; Erik Harris; Julia Krushkal; Larry Rubinstein; James H Doroshow; Beverly A Teicher
Journal:  Cancer Chemother Pharmacol       Date:  2019-05-17       Impact factor: 3.333

Review 2.  Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?

Authors:  Benjamin A Derman; Richard A Larson
Journal:  Best Pract Res Clin Haematol       Date:  2019-10-18       Impact factor: 3.020

3.  Translesion synthesis DNA polymerases η, ι, and ν promote mutagenic replication through the anticancer nucleoside cytarabine.

Authors:  Jung-Hoon Yoon; Jayati Roy Choudhury; Louise Prakash; Satya Prakash
Journal:  J Biol Chem       Date:  2019-11-04       Impact factor: 5.157

4.  Outcomes of HIDAC 18 g Versus IDAC 9 g in Consolidation Therapy of Acute Myeloid Leukemia: A Retrospective Study.

Authors:  Dinesh Ravikumar; Honey Saju; Amit Choudary; Arnab Bhattacharjee; Biswajit Dubashi; Prasanth Ganesan; Smita Kayal
Journal:  Indian J Hematol Blood Transfus       Date:  2021-04-01       Impact factor: 0.900

5.  FLT3-ITD signals bad news for core binding factor acute myeloid leukemia unless trisomy 22 comes to the rescue.

Authors:  Sun Loo; Andrew H Wei
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

6.  JAK-STAT inhibitor as a potential therapeutic opportunity in AML patients resistant to cytarabine and epigenetic therapy.

Authors:  Govind Babu; Padmaparna Chaudhuri; Manoj Rajappa; Manjusha Biswas; Bipinesh Sansar; Chethan Rajegowda; Aneesha Radhakrishnan; Jayshree Advani; Biplab Tewary; Padhma Radhakrishnan; Saravanan Thiyagarajan; Aditi Chatterjee; Ram Shankar Upadhayaya; Pradip K Majumder
Journal:  Cancer Biol Ther       Date:  2020-12-27       Impact factor: 4.742

7.  Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients

Authors:  Gökçen Özcan; Ömür Özlenen Uçakhan
Journal:  Turk J Ophthalmol       Date:  2021-04-29

Review 8.  Bridging Strategies to Allogeneic Transplant for Older AML Patients.

Authors:  Judith Hecker; Isabella Miller; Katharina S Götze; Mareike Verbeek
Journal:  Cancers (Basel)       Date:  2018-07-11       Impact factor: 6.639

9.  Structural basis for polymerase η-promoted resistance to the anticancer nucleoside analog cytarabine.

Authors:  Olga Rechkoblit; Jayati Roy Choudhury; Angeliki Buku; Louise Prakash; Satya Prakash; Aneel K Aggarwal
Journal:  Sci Rep       Date:  2018-08-23       Impact factor: 4.379

Review 10.  Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?

Authors:  Sonia Jaramillo; Richard F Schlenk
Journal:  Curr Oncol Rep       Date:  2021-07-16       Impact factor: 5.075
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.